Global Bipolar Disorder Therapeutic Market - Analysis, Technologies & Forecasts to 2021 - Driven by Need to Reduce Financial Burden of Bipolar Disorder - Research and Markets

DUBLIN, Apr. 25, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Bipolar Disorder Therapeutic Market 2017-2021" report to their offering.

The global bipolar disorder therapeutic market to grow at a CAGR of 2.22% during the period 2017-2021.

The report, Global Bipolar Disorder Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is awareness about bipolar disorder in children (pediatric extension). Although most children experience mood swings as a part of growing up, these mood swings may often persist for a longer period and interfere with the daily life of the child. Bipolar disorder is one of the causes of these mood swings. Although the disease is rarely diagnosed in children, awareness about the disease among children has been rising.

According to the report, one of the major drivers for this market is need to reduce financial burden of bipolar disorder. Mental health disorder has an estimated cost of $100 billion in the US. Similarly, one out of four people in Europe has a mental disorder. The severe effect of mental disorders can be understood from the fact that six out of 20 countries with the highest rates of suicide belong to Europe. To address this scenario, governments and companies are organizing awareness camps to raise disease awareness among the public.

Further, the report states that one of the major factors hindering the growth of this market is lack of adequate diagnostic process. The lack of a proper technical diagnostic process and high dependency on psychiatric diagnosis increases uncertainty in the results obtained. The diagnosis relies significantly on factors such as family history and collaborative information of personal and professional life. Also, doctors are often unable to distinguish bipolar disorder from other mental disorders. Studies indicate an average delay of six years in the diagnosis of people with bipolar disorder.

Key vendors

• Eli Lilly
• Bristol-Myers Squibb
• AstraZeneca

Other prominent vendors

• Allergan
• Astellas Pharma
• GlaxoSmithKline
• Janssen Pharmaceuticals
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Market landscape

PART 07: Pipeline landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

PART 15: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/26rmg4/global_bipolar

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716